LifeSci Capital Downgrades Mereo BioPharma Group to Market Perform

Benzinga Newsdesk Dec 29, 2025 10 months ago

NewsDowngradesAnalyst Ratings

LifeSci Capital analyst Cory Jubinville downgrades Mereo BioPharma Group (NASDAQ:MREO) from Outperform to Market Perform.